1. Introduction {#sec1}
===============

Increased long-term survival following effective treatment of childhood lymphomas has placed greater emphasis on residual sequelae of therapy for lymphoma and the impact of these sequelae as the cause of further morbidity and mortality. Following treatment of childhood Hodgkin\'s disease, cardiac pathology is second only to neoplasm as the cause of death in initial survivors \[[@B1]\]. As the number of cancer survivors increases, so does the number of patients exposed to therapies toxic to the heart and lung, including radiation and chemotherapeutic modalities that employ anthracyclines \[[@B2]\]. The literature is replete regarding effects of anthracyclines and radiation on the heart; however, there is still debate regarding the detection of cardiac sequelae \[[@B3]\], their significance \[[@B4]\], and the relation between different treatment modalities and the development of cardiac sequelae. We hypothesized that protocols employing anthracyclines and radiation would adversely affect long-term cardiac function and that these effects would differ between survivors who received different treatment modalities. We therefore prospectively evaluated long--term cardiac function in 45 survivors of childhood lymphomas, using clinical parameters, electrocardiography, and echocardiography and compared these parameters between lymphoma subtypes.

2. Patients and Methods {#sec2}
=======================

The study included survivors of histology-diagnosed childhood lymphomas who had at least 5 years of followup from termination of therapy, and who were less than 18 years of age at treatment initiation. These criteria identified 45 survivors of 108 children treated for lymphoma at the Pediatric Hematology and Oncology department of a tertiary care center during a nineteen-year period. Fifteen additional survivors meeting these inclusion criteria declined complete participation in the protocol. All participants underwent evaluation which included an interview to assess functional class (New York Heart Association), physical examination, 12-lead electrocardiography (ECG), and echocardiography. Data were taken from a single assessment at the last available follow-up.

Informed consent was obtained from all participants or their legal guardians.

2.1. Statistics {#sec2.1}
---------------

Statistical analysis was performed using a commercially available package (Sigmastat 5.0 Jandel Scientific, San Rafael, California). Comparisons between the different lymphoma subgroups were made using one way ANOVA or the Tukey correction of this test where normality failed, and where relevant by the Student\'s *T*-test or the Mann-Whitney rank sum test where normality failed. Statistical significance was set at *P* \< .05.

2.2. Study Population {#sec2.2}
---------------------

Characteristics of the study population including treatment duration and mean follow-up duration are presented in [Table 1](#tab1){ref-type="table"}.

2.3. Treatment Modalities {#sec2.3}
-------------------------

Tumor characteristics and therapeutic modalities are detailed in [Table 2](#tab2){ref-type="table"}.

The BL subgroup was divided between those treated in earlier years with protocols (COMP) that did not include anthracyclines (7/12 patients), and those that were treated more recently (5/12 patients) with protocols (LMB, NCI) containing anthracyclines. These two subgroups did not differ significantly with regard to age at diagnoses (6.7 ± 3.7; 8.30 ± 5.1 years, resp., *P* = .52) or age at follow-up (21.2 ± 4.2; 16.1 ± 5.8 years, *P* = .1).

The mean dose of doxorubicin (adriamycin), for the group as a whole was 25 mg/m^2^ per treatment, leading to a cumulative dose of 150 mg/m^2^ or a total cumulative dose of 225--250 mg.

All participants underwent evaluation which included an interview to assess functional class (New York Heart Association (NYHA)), physical examination, 12-lead ECG, and echocardiography. Cardiovascular physical examination, ECG, and echocardiography were performed by 2 senior staff pediatric cardiologists (A. Lorber and Y. Braver). Analyses of ECG and echocardiography images were then undertaken in a blinded manner by different investigators (M. Friedberg and I. Solt). Stroke volume was calculated by multiplying the aortic valve area, measured from the 2-dimensional echocardiographic long axis view of the internal aortic diameter at valvular level, with the velocity time integral (VTI) of aortic flow. Cardiac index (CI) was then calculated by multiplying this value by heart rate, and dividing the product by body surface area. Left ventricular indices were measured by M-mode echocardiography. Left ventricular mass was calculated by the Devereux method \[[@B5]\]. Left ventricular diastolic function was assessed from mitral valve inflow Doppler. Mitral regurgitation was graded according to the routine clinical gradation used in the lab as none, trivial, mild, moderate or severe. Echocardiographic data were compared to well-established normal values \[[@B6]\]. Normal values were defined as being within 2 standard deviations of the mean normal value: for LV ejection fraction 66 ± 4%, and LV fractional shortening 36 ± 4%, LV mass index 70.4 gram/m^2^ for males (10--95 percentile 48.5--103 gram/m^2^) and 60.7 gram/m^2^ for females (10--95 percentile 35.6--81 gram/m^2^). Early diastolic mitral inflow velocity (E wave) to late diastolic mitral inflow velocity (A wave) ratio is 1.7 ± 0.4 to 2.5 ± 0.9. Cardiac dimensions were defined as being within 2 standard deviations of the normal mean for body surface area. A QTc \> 0.44 seconds was defined as prolonged.

3. Results {#sec3}
==========

3.1. Functional Capacity and History {#sec3.1}
------------------------------------

All patients had normal cardiovascular function prior to initiation of therapy.

The NYHA functional class was class I in 43 patients (96%) and class II in 2 patients (4%). These 2 patients did not have other comorbidities or notable toxic effects on follow-up. No Raynaud\'s phenomenon was reported. No events of near-syncope, syncope, or sudden death were noted. Clinical features of the cohort as a whole and of the Hodgkin\'s disease subgroup are shown in [Table 3](#tab3){ref-type="table"}.

3.2. Electrocardiography {#sec3.2}
------------------------

All patients demonstrated normal sinus rhythm with no bradycardias or tachycardias noted. The percentage of survivors with a prolonged QTc interval by lymphoma subgroup is shown in [Figure 1(a)](#fig1){ref-type="fig"}. A prolonged QTc interval was not associated with sinoatrial or atrioventricular node dysfunction-conduction anomalies.

Incomplete right bundle branch block was recorded in 4 patients (9%, all diagnoses); complete right bundle branch block was recorded in 2 patients. No evidence of ischemia or "strain" was noted on nonstress ECG.

3.3. Echocardiography {#sec3.3}
---------------------

Cardiac systolic and diastolic function was normal or low-normal for the group as a whole without significant differences between the subgroups ([Table 3](#tab3){ref-type="table"}).

LV mass and shortening fraction did not correlate with mantle irradiation dose, QTc interval, or length of follow-up. Mean LV mass was within normal limits (97 ± 40 grams/m^2^, mean ± S.D.). LV mass was significantly higher for males as compared to females (all subjects, 112 grams versus 76 grams, resp.; *P* \< .01). There was no significant difference in shortening fraction between males and females. Left ventricular end diastolic internal dimensions did not increase following relatively smaller shortening fraction values. Cardiac index and mass by lymphoma subgroup are presented in Figures [1(b)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"}, respectively.

Mild mitral regurgitation was observed in 7 of the 45 patients (16%). The percentage of survivors with mitral regurgitation by subgroup is shown in [Figure 1(d)](#fig1){ref-type="fig"}. Mitral valve prolapse was recorded in 1 HD survivor. Pulmonary valve insufficiency, more than the accepted physiological norm, was found in 1 survivor of NHNB.

Asymptomatic small pericardial effusions were found in 3 of the 45 patients (7%). No larger effusions or pericardial thickening was noted in any of the patients. A mitral inflow pattern consistent with constrictive or restrictive physiology (elevated E wave velocity, elevated E/A ratio, and short deceleration time) was not noted in any of the patients.

Selected electrocardiographic and echocardiographic parameters for the subset of BL survivors treated with anthracyclines versus those not treated with anthracyclines are presented in [Table 4](#tab4){ref-type="table"}.

4. Discussion {#sec4}
=============

Cardiac abnormalities described after treatment for childhood lymphomas can involve almost any aspect of cardiac function and include pericarditis, pericardial effusions, pericardial fibrosis, pancarditis, myocardial fibrosis with functional impairment, valvular disease, conduction defects, and coronary artery disease \[[@B1]\]. Although sequelae may develop at variable time intervals following treatment, emphasis is now placed on the long-term sequelae of lymphoma therapy \[[@B7], [@B8]\], which are caused mainly by anthracyclines and radiation \[[@B9]\].

In our study population, most parameters of cardiac status were within normal limits. This is most likely due to the relatively low dose of anthracyclines used. Previous study has shown that an average cumulative dose of 450 mg/m^2^ of doxorubicin causes a 23% abnormality rate in echocardiographic findings during a 7-year follow-up period \[[@B10]\] and that sequelae are rare at doses under 300 mg/m^2^ \[[@B10], [@B11]\]. Our study population received an average of 150 mg/m^2^ of doxorubicin, leading to a total dose of 225--250 mg, which is less than the average toxic dose. This is achieved in modern protocols through regimens employing multidrug therapy. The average follow-up duration for our population was 10.9 years, which is longer than that of many other studies, with relatively few cardiac sequelae from anthracyclines. However, these patients still warrant long-term cardiac follow-up, as the risk for cardiomyopathy continues to increase over time \[[@B12], [@B13]\]. This vigilance is further justified by previous findings that patients may develop cardiac complications from anthracyclines, even when lower doses are used \[[@B13]\].

Studies performed 2 to 3 decades ago identified factors that augment the cardiotoxicity of anthracyclines. These include radiation of the mediastinum \[[@B14], [@B15]\], previous cardiac abnormalities, including involvement of the heart by the tumor \[[@B16], [@B17]\], uncontrolled hypertension \[[@B11], [@B12]\], and exposure to other chemotherapy modalities such as cyclophosphamide, dactinomycin, mitomycin, vincristine, bleomycin and methotrexate \[[@B13], [@B18], [@B19]\]. Demographic factors include young age, female sex, black race and also trisomy 21 \[[@B7]\]. Among these, our study population was exposed to radiation of up to 4400 cGy (but in most instances less than this) and to polychemotherapy, including vincristine and bleomycin, as dictated by the various treatment protocols. More recently a pathophysiological role for the tyrosine kinase receptor, ErbB2, has been implicated in cardiomyocyte susceptibility to anthracyclines \[[@B20]\].

Again, the total dose of doxorubicin was probably the most important factor in preventing significant cardio toxicity among our population. These findings are consistent with other studies that found that modern protocol therapies using MOPP/ABVD and radiation hold low risk for cardiac toxicity \[[@B21], [@B22]\].

Leandro et al. \[[@B9]\] suggested that cardiac status following anthracyclines is described by a pattern consistent with a thin-walled, compliant left ventricle with reduced muscle mass performing under above-normal levels of wall stress. Our results are consistent with this description and show left ventricular dimensions at the lower level of normal, with good compliance.

It is surprising that no statistical differences in systolic function and left ventricular mass and thickness were found between the lymphoma type subgroups, in the light of the substantial differences in therapy that these groups received. Although differences in left ventricular mass between BL patients who received anthracyclines and those who did not reach statistical significance, our data may correlate with the aforementioned findings that anthracyclines reduce ventricular mass and reduce left ventricular wall thickness. However, no differences were found between the various lymphoma subgroups, among whom HD patients were exposed both to anthracyclines as well as to radiation. Indeed, these patients exhibited increased cardiac output in comparison to the other lymphoma subgroups. We do not have a clear interpretation for this result. More importantly, cardiac index was at the low range of normal, or slightly below normal, for all groups. Differences between males and females were significant regarding LV mass, a factor that contributes to the greater susceptibility of females to anthracyclines \[[@B7]\], and the greater prevalence of prolonged QTc interval among females.

We found an increased prevalence of mitral valve regurgitation in our study population. An earlier study \[[@B26]\] found mitral valve regurgitation in 24% of patients. The significance of mitral valve regurgitation in these patients is not entirely clear. Minimal mitral insufficiency, in the absence of valve deformity, is usually of little clinical significance \[[@B27]\]. However, Allen et al. \[[@B28]\] detected an increase in the prevalence of mitral regurgitation among children who had received anthracyclines, 12% (4 of 34) of whom later developed left ventricular systolic dysfunction, concluding that mitral regurgitation might be an early marker of anthracycline-related cardiac dysfunction.

Seventeen percent of the patients we studied demonstrated a prolonged corrected QT interval. Cardiac dysrhythmias are prevalent in survivors of lymphoma treated with anthracyclines \[[@B29]\]. Our findings correlate with those of previous studies, where both QT and QT dispersion were prolonged following treatment with anthracyclines \[[@B30], [@B31]\]. A prolonged QT interval may result from myocardial cell damage but does not correlate with decreased contractile function \[[@B24], [@B25]\]. As dysrhythmias may occur years after termination of treatment and these are potentially life-threatening, patients should be evaluated at regular followup with a 12-lead ECG \[[@B8], [@B32]\]. Although no sudden death events were observed in our population, following our findings of a prolonged Q-T interval in a substantial percentage of the population, it may be suggested that a 24-hour holter-ECG recording be part of the routine follow-up of these patients.

Coronary artery disease has been reported after radiation therapy to the mediastinum, but not after anthracycline therapy \[[@B1], [@B33]\]. This pathology led to significantly increased mortality at 7-year follow-up. Our results did not show resting ECG changes, and there was no premature mortality among our study group on a longer follow-up period. In the light of findings from other studies, we would suggest periodic ergometry in the long-term follow-up of patients who have undergone radiation therapy \[[@B34]\].

Additional well-described sequelae of radiation therapy to the mediastinum are pericardial effusion and constrictive pericarditis \[[@B35], [@B36]\].We did not note these pathologies to any significant degree in our study population.

The use of possible cardioprotective agents such as dexrazoxane may provide additional protection against long-term cardiac sequelae of anthracyclines, especially in girls \[[@B37], [@B38]\]. These agents were not used in our study, and we cannot comment further on their effects.

LimitationsThis study has certain limitations. This study was performed as a retrospective analysis of data with inherent limitations. The study group is relatively small and the number of patients in subgroups is small. We did not compare the study group with a control group, as our primary objective was definition of cardiac status among survivors. However, we used well-established norms that are commonly and widely used as the basis for this definition. Further comparisons between the different lymphoma subgroups, provided a comparative basis for the different treatment modalities, and specific comparison between Burkitt lymphoma survivors who had been exposed to anthracyclines and those who had not strengthened this comparison. Echocardiographic parameters such as ejection fraction and fractional shortening are limited by load dependency and constitute basic indicators of global ventricular function. Although other echocardiographic methods are available for assessment of cardiac function, each has its specific limitations and in daily clinical practice many oncologists are more familiar with the traditional parameters used in this study. Likewise assessment of left ventricular mass by echocardiography is limited. This study focused on long-term follow-up with data collected at the last available assessment, and we did not collect data on acute or subacute toxicity.In summary, in this cohort, relatively few long-term cardiac complications were seen in most patients following low-dose anthracycline therapy used in modern treatment protocols for childhood lymphoma. However, anthracycline cardio toxicity has previously been well established and in the current study, abnormalities were found in mitral valve regurgitation abnormalities, QT prolongation, low-normal cardiac index, and in 2 survivors functional capacity reduction leading to a compromised quality of life. The greater frequency of abnormalities in females requires increased vigilance in this group. These findings necessitate comprehensive and long-term cardiac follow-up of these patients.

![(a) Percentage of survivors with prolonged QTc interval (\>0.44 s) among the lymphoma subgroups. (b) Cardiac index among the lymphoma subgroups. *N* = 45, Mean + SD, ANOVA *P* \< .01. (c) Left ventricular mass among the lymphoma subgroups. *N* = 45, Mean + SD, ANOVA not significant. (d) Percentage of survivors with mitral regurgitation among the lymphoma subgroups. *N* = 45. H.D.: Hodgkin\'s Disease, B.L.: Burkitt\'s Lymphoma, N.H.N.B.: Non Hodgkin Non Burkitt lymphoma.](CRP2011-316927.001){#fig1}

###### 

Demographic characteristics of survivors by lymphoma subtype.

                                  HD     BL     NHNB   Total/Average
  ------------------------------- ------ ------ ------ -------------------------
  Males (*n*)                     14     7      5      26
  Females (*n*)                   12     5      2      19
  Mean age at diagnosis (years)   10.8   7.4    5.5    9.1 (range: 2.1--16.4)
  Treatment duration (years)      0.9    0.8    1.7    0.94
  Age at follow-up (years)        23.1   19.1   16.7   21 (range: 2.1--16.4)
  Followup duration (years)       11.3   10.9   9.5    10.9 (range: 2.1--16.4)

###### 

Lymphoma characteristics and treatment data of survivors by lymphoma subtype.

  Patient   Staging    Histology   ChemoTx     Irradiation           Total dose (cGy)   Mantle dose (cGy)
  --------- ---------- ----------- ----------- --------------------- ------------------ -------------------
  *HL*                                                                                  
  1         3B         NONE        MOPP        MANTLE                1500               1500
  2         2B         NS          MOPP        MANTLE                3000               3000
  3         2B         NS          MOPP        MANTLE                4000               4000
  4         1A         LP          MOPP        MANTLE                2000               2000
  5         2B         LP          MOPP        MANTLE                4000               4000
  6         3A         MC          MOPP/ABVD   TOT. NODAL            1650               1500
  7         1A         NS          MOPP        MANTLE                2600               2800
  8         2A         MC          MOPP/ABVD   MANTLE                2000               2000
  9         2B         MC          MOPP/ABVD   MANTLE,INV.Y.SPLEEN   5800               4000
  10        2A         NS          MOPP/ABVD   MANTLE                1800               1800
  11        3B         NS          MOPP/ABVD   MANTLE,PARAAORTIC     8000               4000
  12        2B         NS          MOPP/ABVD   MANTLE,INV.Y          4000               4000
  13        2B         MC          MOPP/ABVD   MANTLE                3060               3060
  14        3B         NS          MOPP        MANTLE,INV.Y,SPLEEN   5100               2500
  15        2A         NONE        MOPP        MANTLE,INV.Y          8400               4400
  16        2B-BULKY   MC          MOPP/ABVD   MANTLE                2600               2600
  17        3A         NS          MOPP/ABVD   MANTLE                2600               2600
  18        2A-BULKY   NS          MOPP/ABVD   MANTLE                4000               4000
  19        1A         NS          MOPP/ABVD   MINIMANTLE            3600               3600
  20        2A         NS          MOPP/ABVD   MANTLE                3000               3000
  21        3B         LD          MOPP        MANTLE,INV.Y          8000               4000
  22        2A         NS          MOPP        MANTLE                4000               4000
  23        1A         LP          NONE        MANTLE                4000               4000
  24        2A         NS          MOPP/ABVD   MANTLE                2600               2600
  25        2A         NS          NONE        MANTLE,PARAO,SPLEEN   8000               4000
  26        2B-BULKY   NS          MOPP/ABVD   MANTLE                3000               3000
                                                                                        
  Average                                                            3935               3152
                                                                                        
  *BL*                                                                                  
  27        NP         6           COMP                              0                  0
  28        ABD        6           NCI                               0                  0
  29        ABD        6           LMB                               0                  0
  30        ABD        6           COMP                              0                  0
  31        ABD        6           COMP                              0                  0
  32        ABD        6           COMP                              0                  0
  33        ABD        6           COM                               0                  0
  34        ABD        6           COMP        WHOLE ABDOMEN         1550               0
  35        ABD        6           NCI                               0                  0
  36        ABD        6           LMB                               0                  0
  37        NP         6           ACOMP                             0                  0
  38        ABD        6           NCI                               4000               0
                                                                                        
  Average                                                            462                0
                                                                                        
  *NHNB*                                                                                
  39        0          7           LSAL2                             0                  0
  40        0          7           LSAL2/COM   BRAIN,TOT.LUNG        3600               0
  41        0          7           LSAL2       BRAIN,INV.Y           5600               0
  42        0          7           COM                               0                  0
  43        0          7           LSAL2       MEDIASTINUM           750                0
  44        0          7           LSAL2       MEDIASTINUM           2000               0
  45        0          7           COMP        BRAIN                 2400               0
                                                                                        
  Average                                                            2050               0

MOPP: nitrogen mustard, oncovin, prednisone, and procarbazine; COM/P: cyclophosphamide,oncovin, and methotrexate/prednisone; ABVD: adriamycin, bleomycin, vinblastine, and deticen; NCI: national cancer institute; ACOMP: like comp with adriamycine; LSA2L2: norma wollner protocol; LMB: no abbreviation; NS: nodular sclerosis; LP: lymphocyte predominance; MC: mixed cellularity; LD: lymphocyte depletion.

###### 

Electrocardiographic and echocardiographic data of all survivors and the Hodgkins disease subtype.

                                       All             Hodgkins disease   
  ------------------------------------ --------------- ------------------ -----
  *Electrocardiography*                                                   
  Heart rate (bpm) (mean ± SD)         77 ± 11                            
  PR interval (seconds) (mean ± SD)    0.144 ± 0.024                      
  QTc interval (seconds) (mean ± SD)   0.411 ± 0.032   0.417 ± 0.034      N.S
                                                                          
  *Echocardiography*                                                      
  LV Fractional shortening (%)         40 ± 5.6        39.5 ± 5.6         N.S
  Cardiac Index (L/min/m^2^)           2.84 ± 1.13     3.4 ± 1.03         N.S
  LVED (cm)                            4.43 ± 0.057                       N.S
  Septal thickness (cm)                0.65 ± 0.12     0.65 ± 0.13        N.S
  Posterior wall thickness (cm)        0.66 ± 0.1      0.67 ± 0.1         N.S
  LV mass (gm/m^2^)                    97 ± 40         96 ± 38            N.S
  E/A wave ratio                       2.5 ± 1.3       2.29 ± 1.09        N.S
  Mitral regurgitation (*n*, %)        7/45 (16)       4/26 (15)          N.S

###### 

Comparison of selected electrocardiographic and echocardiographic characteristics between Burkitt lymphoma survivors who received or did not receive anthracyclines as part of their treatment regimen.

                               B.L. patients who received anthracyclines   B.L. patients who did not receive anthracyclines   
  ---------------------------- ------------------------------------------- -------------------------------------------------- -----
  LV shortening fraction (%)   41 ± 5                                      39 ± 3                                             N.S
  QTc                          0.416 ± 0.03                                0.4 ± 0.02                                         N.S
  LV mass                      121 ± 36                                    85 ± 37                                            N.S
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